European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b and poliomyelitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 100 mg - active: lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry   opadry white 00f18296 povidone titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 200 mg - active: lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry black 00f17713 opadry red 00f15613 opadry white 00f18296 povidone titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 400 mg - active: lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium 00f17713 basic coating premix black magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

United States - English - NLM (National Library of Medicine)

novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluorescein sodium -

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.